Episode 106
On this week’s Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Eric Schmidt, Sam Fazeli, Bruce Booth and Grace Colon discuss the big news of the week including the FDA granting a landmark expanded approval for Sarepta’s Elevidys for patients with Duchenne Muscular Dystrophy. The ho…
Episode 116
On this week’s episode of Biotech Hangout, hosts Chris Garabedian, Bruce Booth, Josh Schimmer, Eric Schmidt and Sam Fazeli start the show on the topic of M&A and ponder “where are the deals?” as they consider potential
reasons such as the U.S. election, too few assets or too few buyers. The convers…
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new …
Episode 122 - November 22, 2024
On this episode of Biotech Hangout, Eric Schmidt, Bruce Booth, Yaron Werber, Tim Opler and Mike Yee begin the show discussing the highlights from the Jefferies Healthcare Conference before taking a look at public investor sentiment this week. The discussion turns to Atlas Venture’s 2024 Year in Rev…
Episode 136 - March 28, 2025
On this week’s episode, Chris Garabedian, Tim Opler, Bruce Booth, and Sam Fazeli discuss the current investor mood, a PIPEs retrospective, and the contraction of new startups. The episode opens with a conversation on the biotech market updates, which have been driven by economic uncertainty and shi…
Episode 89: Preparing for BIO 2025 – Key Strategies to Maximize Biotech Conference Success
Are you ready to make the most of your time at BIO 2025?
In this episode, hosts Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, break down everything biotech leaders need to know about the spring conference season and how to strategically prepare for the BIO International Convention in Boston…
Episode 25: Atlas Venture's Bruce Booth
Bruce Booth discusses his education and early career, the structure of Atlas and the types of investments it makes, investing in assets vs platforms, and more.
Episode 161 - October 31, 2025
On this week’s episode, Daphne Zohar, Bruce Booth, Sam Fazeli, Brian Skorney, Yaron Werber, and Eric Schmidt kick off with market updates, noting that the XBI is showing signs of a sustainable recovery after years of underperformance and highlighting that the IPO market is likely closed for the rem…
382: Biotech's year in review
Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays?
We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at vent…
Episode 167 - December 19, 2025
On the final episode of 2025, Daphne Zohar, Bruce Booth, and Eric Schmidt kick off with a general market overview, including a look back at 2025 and some predictions for 2026. The co-hosts discuss biotech rebounding in the last few months of 2025 after years of underperformance, driven by macro rot…
PODCAST SEARCH ENGINE
You can use our website to search 3,824,033 podcasts and 195,710,248 episodes by people, places, or topics.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
EDIT
Thank you for helping to keep the podcast database up to date.
